Clinical Trials Logo

Solid Metastatic Tumor clinical trials

View clinical trials related to Solid Metastatic Tumor.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04134312 Completed - Clinical trials for Solid Metastatic Tumor

A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer

Start date: January 8, 2020
Phase: Phase 1
Study type: Interventional

A Phase 1 open label trial of intravenous administration of MVA-BN-Brachyury vaccine in patients with advanced cancer. Patients with metastatic or unresectable locally advanced malignant solid tumors will be enrolled and treated according to a 3+3 dose escalation scheme. Up to 3 dose levels will be explored. Patients will receive MVA-BN-Brachyury every three weeks, three administrations in total. Patients will be hospitalized after each vaccination, over 48 hours. Trial duration will be approximately 24 weeks per patient including 3 months after the last vaccination follow up (FU) period.